Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Incoming Orders/Contract
Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
06.07.2022 / 09:13
The issuer is solely responsible for the content of this announcement.

Berlin, 6 July 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225. The agreement covers the development of a validated manufacturing process as well as the GMP-compliant production of clinical investigational products. Ratio Therapeutics will use the newly built GMP suites at the Eckert & Ziegler production site near Boston, MA, USA, from July 2022 for this purpose.

"The growing interest in radiopharmaceuticals is creating a huge demand for expertise in the development and manufacture of investigational products. Due to the need to reduce costs, the pharmaceutical industry has initiated a paradigm shift in recent years - from a vertically integrated business model to a more cost-efficient supplier network. With our new GMP suites and our many years of know-how, we support the pharmaceutical industry in bringing their radiopharmaceuticals to market more quickly," explains Dr. Lutz Helmke, Executive Director and Chief Operating Officer at Eckert & Ziegler for the Medical segment.

“With Eckert & Ziegler, we have an established partner with best-in-class radiopharmaceutical manufacturing capabilities for medical and scientific use,” commented Dr. Matthias Friebe, Chief Technology Officer at Ratio Therapeutics. “Their expertise in radiopharmaceutical manufacturing will ensure high-quality products and robust manufacturing and logistics expertise for our upcoming clinical programs as we rapidly move toward the submission of our first investigational new drug (IND) application.”

The Eckert & Ziegler radiopharmaceutical production facility in Boston, MA, USA, has state-of-the-art hot cells for alpha, beta and gamma emitters, radiosynthesis, quality control and other equipment for production under GMP conditions. The rentable clean room suites are optimized for carrying out processes for the production of radiopharmaceuticals.

With the GMP facility, Eckert & Ziegler offers both regional and global pharmaceutical companies a one-stop service for a variety of radiopharmaceutical services under GMP and cGMP conditions. These include complete early development services including process development and scale-up, CMC manufacturing and packaging, product release and stability programs. As a radiopharmaceutical contract manufacturer, Eckert & Ziegler is able to produce small batches for Phase I, II and III clinical studies and large commercially applicable batch sizes.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

About Ratio Therapeutics.
Ratio Therapeutics Inc. is a Boston-based pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and, thus, transform oncology treatment paradigms. Ratio’s fully integrated proprietary R&D platforms, Trillium™ and Macropa™, enable the imaging, discovery and advancement of novel radiopharmaceuticals that have first/best-in-class delivery, safety and efficacy properties. The tunable nature of the company’s platforms allows the generation in an efficient and timely manner of numerous novel radiopharmaceuticals for a broad range of high unmet need in solid tumors. Please visit www.ratiotx.com for more information and follow us on Twitter and LinkedIn.

Contact:
Eckert & Ziegler AG
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Karolin Riehle, Investor Relations / Jan Schöpflin, Marketing
karolin.riehle@ezag.de / jan.schoepflin@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com  

Ratio Therapeutics Media Contact:
Russo Partners, LLC
Erica Fiorini, Ph.D.
Erica.fiorini@russopartnersllc.com  
+1 (914) 310 81-72

06.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de